Cargando…

The Risk of Venous Thromboembolism (VTE) in Men with Benign Prostatic Hyperplasia Treated with 5-Alpha Reductase Inhibitors (5ARIs).

BACKGROUND: Many men receive 5-alpha reductase inhibitors (5ARIs) for ongoing treatment of benign prostatic hyperplasia (BPH). The increased risk of cardiovascular complications with 5ARIs has been documented in BPH studies and the occurrence of cerebral venous thrombosis, presumably due to increase...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ayodele, Olulade, Cabral, Howard J, McManus, David, Jick, Susan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2021
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8349190/ https://www.ncbi.nlm.nih.gov/pubmed/34377032 http://dx.doi.org/10.2147/CLEP.S317019

Ejemplares similares

Glucocorticoids and Risk of Venous Thromboembolism in Asthma Patients Aged 20–59 Years in the United Kingdom’s CPRD 1995–2015
por: Ayodele, Olulade A, et al.
Publicado: (2022)

Risk of gynecomastia and breast cancer associated with the use of 5-alpha reductase inhibitors for benign prostatic hyperplasia
por: Hagberg, Katrina Wilcox, et al.
Publicado: (2017)

The use of 5-alpha reductase inhibitors in the treatment of benign prostatic hyperplasia
por: Kim, Eric H., et al.
Publicado: (2018)

Metabolomic Profile in Venous Thromboembolism (VTE)
por: Franczyk, Beata, et al.
Publicado: (2021)

5-alpha reductase inhibitors (5-ARi) with or without alpha-blockers (α-B) for Benign Prostatic Hyperplasia do NOT lower the risk of incident Bladder Cancer: United States insurance claims data
por: Del Giudice, Francesco, et al.
Publicado: (2023)

Hokusai-VTE: Edoxaban for the treatment of venous thromboembolism
por: Said, Karim
Publicado: (2013)

Effect of 5-alpha Reductase Inhibitor on Storage Symptoms in Patients with Benign Prostatic Hyperplasia
por: Cho, Kang Jun, et al.
Publicado: (2011)

Clinical Effects of Discontinuing 5-Alpha Reductase Inhibitor in Patients With Benign Prostatic Hyperplasia
por: Kim, Won, et al.
Publicado: (2014)

Molecular Correlates of Venous Thromboembolism (VTE) in Ovarian Cancer
por: Glassman, Deanna, et al.
Publicado: (2022)

Are hospitals delivering appropriate VTE prevention? The venous thromboembolism study to assess the rate of thromboprophylaxis (VTE start)
por: Amin, A., et al.
Publicado: (2009)

Systematic review of prognostic models for recurrent venous thromboembolism (VTE) post-treatment of first unprovoked VTE
por: Ensor, Joie, et al.
Publicado: (2016)

Venous thromboembolism (VTE) risk assessment completion in psychiatric inpatients
por: Powell, Harriet, et al.
Publicado: (2021)

Pregnancy-Associated Venous Thromboembolism: Insights from GARFIELD-VTE
por: Jerjes-Sánchez, Carlos, et al.
Publicado: (2021)

Blood Being Tricky: Anticoagulation-Resistant Venous Thromboembolism (VTE)
por: Tiperneni, Raghu, et al.
Publicado: (2022)

Efficacy and safety of 5 alpha-reductase inhibitor monotherapy in patients with benign prostatic hyperplasia: A meta-analysis
por: Kim, Jae Heon, et al.
Publicado: (2018)

Persistence and adherence to dutasteride/tamsulosin fixed-dose versus free-combination alpha blocker/5ARI therapy in patients with benign prostate hyperplasia in Germany
por: Eisen, Christoph, et al.
Publicado: (2020)

A Survey of Venous Thromboembolism (VTE) Prophylaxis in Obstetrics Patients in Iran
por: Mokhtari, Majid, et al.
Publicado: (2019)

Provoked versus unprovoked venous thromboembolism: Findings from GARFIELD‐VTE
por: Ageno, Walter, et al.
Publicado: (2021)

Lessons from the Johns Hopkins Multi-Disciplinary Venous Thromboembolism (VTE) Prevention Collaborative
por: Streiff, Michael B, et al.
Publicado: (2012)

Protocol for a systematic review of prognostic models for the recurrence of venous thromboembolism (VTE) following treatment for a first unprovoked VTE
por: Ensor, Joie, et al.
Publicado: (2013)

Venous thromboembolism (VTE) prophylaxis in severely injured patients: an international comparative assessment
por: Gunning, Amy C., et al.
Publicado: (2019)

Recurrent venous thromboembolism and bleeding with extended anticoagulation: the VTE-PREDICT risk score
por: de Winter, Maria A, et al.
Publicado: (2023)

Venous Thromboembolism (VTE) in Post-Prostatectomy Patients: Systematic Review and Meta-Analysis
por: Wani, Mudassir, et al.
Publicado: (2023)

Berberine Improves Benign Prostatic Hyperplasia via Suppression of 5 Alpha Reductase and Extracellular Signal-Regulated Kinase in Vivo and in Vitro
por: Youn, Dong-Hyun, et al.
Publicado: (2018)

5-α reductase inhibitors, benign prostatic hyperplasia, and risk of male breast cancer
por: Robinson, David, et al.
Publicado: (2015)

Meta-analysis and suggested guidelines for prevention of venous thromboembolism (VTE) in foot and ankle surgery
por: Calder, James D. F., et al.
Publicado: (2016)

Evaluation of the predictive value of the bleeding prediction score VTE‐BLEED for recurrent venous thromboembolism
por: Klok, Frederikus A., et al.
Publicado: (2019)

Venous thromboembolism in Japanese patients with breast cancer: subgroup analysis of the Cancer-VTE Registry
por: Ohsumi, Shozo, et al.
Publicado: (2023)

Incidence and risk factors for venous thromboembolism in the Cancer-VTE Registry stomach cancer subcohort
por: Yoshikawa, Takaki, et al.
Publicado: (2023)

Incidence and risk factors for venous thromboembolism in the Cancer-VTE Registry pancreatic cancer subcohort
por: Okusaka, Takuji, et al.
Publicado: (2023)

Corrigendum: Berberine Improves Benign Prostatic Hyperplasia via Suppression of 5 Alpha Reductase and Extracellular Signal-Regulated Kinase in Vivo and in Vitro
por: Youn, Dong-Hyun, et al.
Publicado: (2019)

Anti-oncogenic effects of dutasteride, a dual 5-alpha reductase inhibitor and a drug for benign prostate hyperplasia, in bladder cancer
por: Seok, Jaekwon, et al.
Publicado: (2023)

Incidence of Symptomatic Venous Thromboembolism (VTE) in 8,885 Elective Total Hip Arthroplasty Patients Receiving Post-operative Aspirin VTE Prophylaxis
por: Coveney, Eamonn I, et al.
Publicado: (2023)

Cardiovascular Outcomes of α-Blockers vs 5-α Reductase Inhibitors for Benign Prostatic Hyperplasia
por: Zhang, Jiandong, et al.
Publicado: (2023)

Gamma Irradiated Rhodiola sachalinensis Extract Ameliorates Testosterone-Induced Benign Prostatic Hyperplasia by Downregulating 5-Alpha Reductase and Restoring Testosterone in Rats
por: Xin, Qi, et al.
Publicado: (2019)

The management of acute venous thromboembolism in clinical practice: Results from the European PREFER in VTE Registry
por: Cohen, Alexander T., et al.
Publicado: (2017)

Prediction of Major Bleeding in Anticoagulated Patients for Venous Thromboembolism: Comparison of the RIETE and the VTE-BLEED Scores
por: Lecumberri, Ramón, et al.
Publicado: (2021)

Venous thromboembolism (VTE) prevention and diagnosis in COVID-19: Practice patterns and outcomes at 33 hospitals
por: Parks, Anna L., et al.
Publicado: (2022)

Clinicopathological Characteristics of Cancer-Associated Venous Thromboembolism (CAT-VTE) from a Medicolegal Autopsy
por: Ro, Ayako, et al.
Publicado: (2022)

Incidence and risk factors for venous thromboembolism, bleeding, and death in colorectal cancer (Cancer‐VTE Registry)
por: Ikeda, Masataka, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_72cakqe35arvrngtv42gjt6j5h